Propentofylline: Difference between revisions

	WikiDoc Resources for Propentofylline
Articles
Most recent articles on Propentofylline Most cited articles on Propentofylline Review articles on Propentofylline Articles on Propentofylline in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Propentofylline Images of Propentofylline Photos of Propentofylline Podcasts & MP3s on Propentofylline Videos on Propentofylline
Evidence Based Medicine
Cochrane Collaboration on Propentofylline Bandolier on Propentofylline TRIP on Propentofylline
Clinical Trials
Ongoing Trials on Propentofylline at Clinical Trials.gov Trial results on Propentofylline Clinical Trials on Propentofylline at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Propentofylline NICE Guidance on Propentofylline NHS PRODIGY Guidance FDA on Propentofylline CDC on Propentofylline
Books
Books on Propentofylline
News
Propentofylline in the news Be alerted to news on Propentofylline News trends on Propentofylline
Commentary
Blogs on Propentofylline
Definitions
Definitions of Propentofylline
Patient Resources / Community
Patient resources on Propentofylline Discussion groups on Propentofylline Patient Handouts on Propentofylline Directions to Hospitals Treating Propentofylline Risk calculators and risk factors for Propentofylline
Healthcare Provider Resources
Symptoms of Propentofylline Causes & Risk Factors for Propentofylline Diagnostic studies for Propentofylline Treatment of Propentofylline
Continuing Medical Education (CME)
CME Programs on Propentofylline
International
Propentofylline en Espanol Propentofylline en Francais
Business
Propentofylline in the Marketplace Patents on Propentofylline
Experimental / Informatics
List of terms related to Propentofylline

Propentofylline
Clinical data
AHFS/Drugs.com	International Drug Names
ATC code	N06BC02 (WHO) Template:ATCvet;
Identifiers
	IUPAC name 3-methyl-1-(5-oxohexyl)-7-propyl-3,7-dihydro-1H-purine-2,6-dione;
CAS Number	55242-55-2 ;
PubChem CID	4938;
UNII	5RTA398U4H;
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Formula	C15H22N4O3
Molar mass	306.360 g/mol
(verify)

VisualWikitext

Latest revision as of 17:01, 20 August 2015

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Propentofylline (HWA 285) is a xanthine derivative with purported neuroprotective effects.

Pharmacology

It is a phosphodiesterase inhibitor.^[1]

It also acts as an adenosine reuptake inhibitor.^[1]^[2]^[3]

Uses

It was studied as a possible treatment for Alzheimer's disease and multi-infarct dementia.^[4]^[5]

Propentofylline has also been studied, to a lesser extent, as a possible adjunct in the treatment of ischemic stroke, due to its vasodilating properties.^[6]^[7]

Propentofylline is in use in veterinary medicine as a geriatric preparation for old dogs.

References

↑ ^1.0 ^1.1 Frampton M, Harvey RJ, Kirchner V (2003). Frampton, Maria A, ed. "Propentofylline for dementia". Cochrane Database Syst Rev (2): CD002853. doi:10.1002/14651858.CD002853. PMID 12804440.
↑ Salimi S; Fotouhi A; Ghoreishi A; et al. (April 2008). "A placebo controlled study of the propentofylline added to risperidone in chronic schizophrenia". Prog. Neuropsychopharmacol. Biol. Psychiatry. 32 (3): 726–732. doi:10.1016/j.pnpbp.2007.11.021. PMID 18096287. Unknown parameter |author-separator= ignored (help)
↑ Numagami Y, Marro PJ, Mishra OP, Delivoria-Papadopoulos M (June 1998). "Effect of propentofylline on free radical generation during cerebral hypoxia in the newborn piglet". Neuroscience. 84 (4): 1127–1133. doi:10.1016/S0306-4522(97)00542-3. PMID 9578400.
↑ Frampton M, Harvey RJ, Kirchner V (2003). Frampton, Maria A, ed. "Propentofylline for dementia". Cochrane database of systematic reviews (Online) (2): CD002853. doi:10.1002/14651858.CD002853. PMID 12804440.
↑ Kittner B, Rössner M, Rother M (1997). "Clinical trials in dementia with propentofylline". Ann. N. Y. Acad. Sci. 826: 307–316. doi:10.1111/j.1749-6632.1997.tb48481.x. PMID 9329701.
↑ Bath PM, Bath-Hextall FJ (2004). Bath, Philip MW, ed. "Pentoxifylline, propentofylline and pentifylline for acute ischaemic stroke". Cochrane database of systematic reviews (Online) (3): CD000162. doi:10.1002/14651858.CD000162.pub2. PMID 15266424.
↑ Huber M, Kittner B, Hojer C, Fink GR, Neveling M, Heiss WD (1993). "Effect of propentofylline on regional cerebral glucose metabolism in acute ischemic stroke". J. Cereb. Blood Flow Metab. 13 (3): 526–30. doi:10.1038/jcbfm.1993.68. PMID 8478410.

Template:Phosphodiesterase inhibitors

[pmid12804440-1] 1.0 ^1.1 Frampton M, Harvey RJ, Kirchner V (2003). Frampton, Maria A, ed. "Propentofylline for dementia". Cochrane Database Syst Rev (2): CD002853. doi:10.1002/14651858.CD002853. PMID 12804440.

[pmid18096287-2] Salimi S; Fotouhi A; Ghoreishi A; et al. (April 2008). "A placebo controlled study of the propentofylline added to risperidone in chronic schizophrenia". Prog. Neuropsychopharmacol. Biol. Psychiatry. 32 (3): 726–732. doi:10.1016/j.pnpbp.2007.11.021. PMID 18096287. Unknown parameter |author-separator= ignored (help)

[pmid9578400-3] Numagami Y, Marro PJ, Mishra OP, Delivoria-Papadopoulos M (June 1998). "Effect of propentofylline on free radical generation during cerebral hypoxia in the newborn piglet". Neuroscience. 84 (4): 1127–1133. doi:10.1016/S0306-4522(97)00542-3. PMID 9578400.

[4] Frampton M, Harvey RJ, Kirchner V (2003). Frampton, Maria A, ed. "Propentofylline for dementia". Cochrane database of systematic reviews (Online) (2): CD002853. doi:10.1002/14651858.CD002853. PMID 12804440.

[5] Kittner B, Rössner M, Rother M (1997). "Clinical trials in dementia with propentofylline". Ann. N. Y. Acad. Sci. 826: 307–316. doi:10.1111/j.1749-6632.1997.tb48481.x. PMID 9329701.

[6] Bath PM, Bath-Hextall FJ (2004). Bath, Philip MW, ed. "Pentoxifylline, propentofylline and pentifylline for acute ischaemic stroke". Cochrane database of systematic reviews (Online) (3): CD000162. doi:10.1002/14651858.CD000162.pub2. PMID 15266424.

[7] Huber M, Kittner B, Hojer C, Fink GR, Neveling M, Heiss WD (1993). "Effect of propentofylline on regional cerebral glucose metabolism in acute ischemic stroke". J. Cereb. Blood Flow Metab. 13 (3): 526–30. doi:10.1038/jcbfm.1993.68. PMID 8478410.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

@@ Line 3: / Line 3: @@
 | verifiedrevid = 447813620
 | IUPAC_name = 3-methyl-1-(5-oxohexyl)-7-propyl-3,7-dihydro-1''H''-purine-2,6-dione
-| image = Propentofylline.svg
+| image = Propentofylline.png
 <!--Clinical data-->
@@ Line 41: / Line 41: @@
 | molecular_weight = 306.360 g/mol
 }}
+              __NOTOC__
+{{SI}}
+{{CMG}}
+==Overview==
 '''Propentofylline''' ('''HWA 285''') is a [[xanthine]] derivative with purported [[neuroprotective]] effects.
@@ Line 46: / Line 52: @@
 It is a [[phosphodiesterase inhibitor]].<ref name="pmid12804440">{{cite journal |author=Frampton M, Harvey RJ, Kirchner V |title=Propentofylline for dementia |journal=Cochrane Database Syst Rev |volume= |issue=2 |pages=CD002853 |year=2003 |pmid=12804440 |doi=10.1002/14651858.CD002853 |editor1-last=Frampton |editor1-first=Maria A}}</ref>
-It also acts as an [[adenosine reuptake inhibitor]].<ref name="pmid12804440">{{cite journal |author=Frampton M, Harvey RJ, Kirchner V |title=Propentofylline for dementia |journal=[[Cochrane Database Syst Rev]] |volume= |issue=2 |pages=CD002853 |year=2003 |pmid=12804440 |doi=10.1002/14651858.CD002853 |editor1-last=Frampton |editor1-first=Maria A}}</ref><ref name="pmid18096287">{{cite journal |author=Salimi S |title=A placebo controlled study of the propentofylline added to risperidone in chronic schizophrenia |journal=Prog. Neuropsychopharmacol. Biol. Psychiatry |volume=32 |issue=3 |pages=726–732 |date=April 2008 |pmid=18096287 |doi=10.1016/j.pnpbp.2007.11.021 |url=http://linkinghub.elsevier.com/retrieve/pii/S0278-5846(07)00411-3 |author-separator=, |author2=Fotouhi A |author3=Ghoreishi A |display-authors=3 |last4=Derakhshan |first4=M |last5=Khodaieardakani |first5=M |last6=Mohammadi |first6=M |last7=Noorbala |first7=A |last8=Ahmadiabhari |first8=S |last9=Hajiazim |first9=M}}</ref><ref name="pmid9578400">{{cite journal |author=Numagami Y, Marro PJ, Mishra OP, Delivoria-Papadopoulos M |title=Effect of propentofylline on free radical generation during cerebral hypoxia in the newborn piglet |journal=Neuroscience |volume=84 |issue=4 |pages=1127–1133 |date=June 1998 |pmid=9578400 |doi= 10.1016/S0306-4522(97)00542-3|url=http://linkinghub.elsevier.com/retrieve/pii/S0306-4522(97)00542-3}}</ref>
+It also acts as an adenosine reuptake inhibitor.<ref name="pmid12804440">{{cite journal |author=Frampton M, Harvey RJ, Kirchner V |title=Propentofylline for dementia |journal=[[Cochrane Database Syst Rev]] |volume= |issue=2 |pages=CD002853 |year=2003 |pmid=12804440 |doi=10.1002/14651858.CD002853 |editor1-last=Frampton |editor1-first=Maria A}}</ref><ref name="pmid18096287">{{cite journal |author=Salimi S |title=A placebo controlled study of the propentofylline added to risperidone in chronic schizophrenia |journal=Prog. Neuropsychopharmacol. Biol. Psychiatry |volume=32 |issue=3 |pages=726–732 |date=April 2008 |pmid=18096287 |doi=10.1016/j.pnpbp.2007.11.021 |url=http://linkinghub.elsevier.com/retrieve/pii/S0278-5846(07)00411-3 |author-separator=, |author2=Fotouhi A |author3=Ghoreishi A |display-authors=3 |last4=Derakhshan |first4=M |last5=Khodaieardakani |first5=M |last6=Mohammadi |first6=M |last7=Noorbala |first7=A |last8=Ahmadiabhari |first8=S |last9=Hajiazim |first9=M}}</ref><ref name="pmid9578400">{{cite journal |author=Numagami Y, Marro PJ, Mishra OP, Delivoria-Papadopoulos M |title=Effect of propentofylline on free radical generation during cerebral hypoxia in the newborn piglet |journal=Neuroscience |volume=84 |issue=4 |pages=1127–1133 |date=June 1998 |pmid=9578400 |doi= 10.1016/S0306-4522(97)00542-3|url=http://linkinghub.elsevier.com/retrieve/pii/S0306-4522(97)00542-3}}</ref>
 ==Uses==